Heart failure pharmacotherapy and cancer : pathways and pre-clinical/clinical evidence
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology..
Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
European heart journal - 45(2024), 14 vom: 07. Apr., Seite 1224-1240 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sayour, Nabil V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurheartj/ehae105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369317947 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369317947 | ||
| 003 | DE-627 | ||
| 005 | 20240425233038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehae105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369317947 | ||
| 035 | |a (NLM)38441940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sayour, Nabil V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heart failure pharmacotherapy and cancer |b pathways and pre-clinical/clinical evidence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. | ||
| 520 | |a Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiotensin receptor blocker | |
| 650 | 4 | |a Angiotensin receptor-neprilysin inhibitor | |
| 650 | 4 | |a Angiotensin-converting enzyme inhibitor | |
| 650 | 4 | |a Beta-blocker | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cardio-oncology | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Mineralocorticoid Receptor antagonist | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 inhibitor | |
| 700 | 1 | |a Paál, Ágnes M |e verfasserin |4 aut | |
| 700 | 1 | |a Ameri, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Meijers, Wouter C |e verfasserin |4 aut | |
| 700 | 1 | |a Minotti, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Andreadou, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Lombardo, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Camilli, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Drexel, Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Grove, Erik Lerkevang |e verfasserin |4 aut | |
| 700 | 1 | |a Dan, Gheorghe Andrei |e verfasserin |4 aut | |
| 700 | 1 | |a Ivanescu, Andreea |e verfasserin |4 aut | |
| 700 | 1 | |a Semb, Anne Grete |e verfasserin |4 aut | |
| 700 | 1 | |a Savarese, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrev, Dobromir |e verfasserin |4 aut | |
| 700 | 1 | |a Crea, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Kaski, Juan-Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Rudolf A |e verfasserin |4 aut | |
| 700 | 1 | |a Ferdinandy, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Varga, Zoltán V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g 45(2024), 14 vom: 07. Apr., Seite 1224-1240 |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:14 |g day:07 |g month:04 |g pages:1224-1240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehae105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 14 |b 07 |c 04 |h 1224-1240 | ||